For in-vitro research use only · Not for human consumption · Not medical advice
The Visceral Fat Researcher's Compound
The only growth hormone-releasing compound that's actually received regulatory approval for a specific condition. Researchers study it primarily for its effects on stubborn belly fat and body composition.
Molecular Weight
5,135.83 Da
CAS Number
218949-48-5
Structure
GHRH(1-44) analog
In Plain English
Visceral fat — the fat packed around your organs, not the pinchable kind under your skin — is the most metabolically dangerous type. It acts like an endocrine organ, pumping out inflammatory signals that drive insulin resistance, cardiovascular risk, and chronic disease. And it's notoriously resistant to diet and exercise alone.
Tesamorelin is a synthetic analog of your body's GHRH (Growth Hormone Releasing Hormone) with the complete 44-amino-acid sequence plus a trans-3-hexenoic acid modification for stability. It received FDA approval in 2010 for the reduction of excess abdominal fat in HIV research subjects with lipodystrophy — making it the most clinically validated GHRH analog available.
What makes Tesamorelin particularly interesting to researchers is that its effects on visceral fat appear selective. Studies show reductions in trunk fat without the significant changes in subcutaneous fat or the metabolic complications that exogenous growth hormone sometimes produces. The mechanism appears to involve enhanced lipolysis specifically in visceral adipose tissue.
Beyond fat metabolism, Tesamorelin has been studied for cognitive effects. Research in older adults showed improvements in verbal memory and executive function, suggesting that GH/IGF-1 axis restoration may have benefits beyond body composition.
Plain English: Tesamorelin is a full-length GHRH analog with actual regulatory approval. It tells the pituitary to release GH, and research shows it selectively reduces the dangerous visceral fat around organs while preserving the body's natural feedback systems.
How It Works
Unlike CJC-1295 (a truncated analog), Tesamorelin preserves the complete 44-amino-acid GHRH sequence. The trans-3-hexenoic acid modification protects it from DPP-IV enzymatic degradation, extending its functional half-life while maintaining the full native receptor interaction.
The GH released by Tesamorelin stimulation triggers lipolysis preferentially in visceral adipose tissue. Research shows significant reductions in trunk fat (measured by CT scan) without proportional changes in subcutaneous fat — suggesting a selective mechanism on deep abdominal fat stores.
Beyond direct fat reduction, Tesamorelin has been studied for improvements in triglyceride levels and other lipid markers. The reduction in visceral fat may itself drive downstream improvements in metabolic health, as visceral adipose tissue is a major source of inflammatory cytokines.
Evidence
Visceral Fat
Phase III clinical trials demonstrated an average 15-18% reduction in visceral adipose tissue (VAT) measured by CT scan over 26 weeks. Notably, these reductions occurred without significant changes in HbA1c or glucose tolerance.
Takeaway: Tesamorelin selectively targets the most metabolically dangerous fat depot without worsening glucose metabolism — a key concern with other GH therapies.
Cognitive Function
A study in older adults (50-70 years) showed that Tesamorelin improved verbal memory and executive function compared to placebo over 20 weeks, particularly in subjects with higher baseline amyloid-beta levels.
Takeaway: GH/IGF-1 axis restoration may have cognitive benefits beyond metabolic effects — an emerging area of aging research.
Body Composition
Clinical data showed that Tesamorelin's fat reduction occurred alongside preservation of lean body mass. This is significant because many fat-loss interventions also cause muscle loss — Tesamorelin's GH-mediated effects appear to protect against this.
Takeaway: Losing fat while keeping muscle is the holy grail of body composition research — Tesamorelin appears to support this balance.
Regulatory Validation
Tesamorelin is the only GHRH analog to achieve FDA approval (2010, for HIV-associated lipodystrophy). This regulatory milestone means it has undergone the most rigorous clinical evaluation of any compound in its class — Phase I through Phase III trials with thousands of subjects.
Takeaway: Regulatory approval represents the highest bar of clinical evidence. No other GHRH analog has cleared this threshold.
AminoVita Research Compound
$54.99
99%+ purity · Third-party tested · 5 mg
View ProductSubscribe & Save 10% — Free shipping on every order
Further Reading
Mechanism Deep Dive
The clinical evidence behind Tesamorelin's effects on visceral fat, body composition, and the GH/IGF-1 signaling cascade.
Wellness Science
The relationship between growth hormone, IGF-1, body composition, and why stubborn fat and stubborn muscle often share the same underlying cause.
FAQ
It's the only GHRH analog to complete the full FDA approval process, including Phase I, II, and III clinical trials with thousands of participants. This level of clinical scrutiny is far beyond what other GHRH analogs have undergone.
Tesamorelin is a full 44-amino-acid GHRH analog (the complete native sequence) with a trans-3-hexenoic acid modification. CJC-1295 is a truncated 30-amino-acid fragment with amino acid substitutions and an optional DAC modification. Tesamorelin has regulatory approval; CJC-1295 does not.
Subcutaneous fat is the "pinchable" fat under your skin. Visceral fat wraps around your internal organs. While subcutaneous fat is relatively metabolically inert, visceral fat acts like an endocrine organ — secreting inflammatory cytokines that drive insulin resistance, cardiovascular disease, and systemic inflammation.
Clinical trials showed that Tesamorelin's visceral fat reduction occurred without significant worsening of HbA1c or glucose tolerance. This is noteworthy because exogenous GH can impair insulin sensitivity. Tesamorelin's physiological, pulsatile GH release appears to avoid this concern.
Not sure where to start? Browse compounds by research goal and find the right combination for your objectives.
Browse CatalogFor in-vitro research use only. Not for human consumption. The information on this page is for educational purposes only and does not constitute medical advice or a recommendation for human use. No claims are made regarding the diagnosis, studyment, is studied in, or prevention of any condition.
